Company: OSRH
Filing Date: 2025-05-20
Form Type: 10-Q
Source: 0001213900-25-045947
Chunk: 331

Company: OSR Holdings, Inc.
Filing Date: 2025-05-20
Form: 10-Q
Item: Part I, Item 8
Chunk 331
---
 in brokerage fees
and costs that the plaintiff alleges are due and owing.

Item 1A. Risk
Factors

In
addition to the risk factors set forth below and the other information set forth in this report, you should carefully consider the factors
discussed under Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for
the fiscal year ended December 31, 2024 filed with the SEC on April 17, 2024 (or “2024 Annual Report”), in our
prospectus dated February 9, 2023 (“IPO Prospectus”), and in the other reports we file with the SEC before making a
decision to invest in our securities. These factors could materially adversely affect our business, financial condition, liquidity, results
of operations and capital position, and could cause our actual results to differ materially from our historical results or the results
contemplated by the forward-looking statements contained in this report or we could face liquidation. In that event, the trading price
of our securities could decline, and you could lose all or part of your investment. The risks and uncertainties described in our 2024
Annual Report, IPO Prospectus and other reports we filed with the SEC and below are not the only ones we face. Additional risks and uncertainties
that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business,
financial condition and operating results. Except as disclosed below, there have been no material changes to the risk factors described
in Part I, Item 1A, “Risk Factors,” included in our 2024 Annual Report.

Item 2. Unregistered
Sales of Equity Securities and Use of Proceeds

Pursuant
to the terms of an Equity Line of Credit Agreement comprising a Common Stock Purchase Agreement and a Registration Rights Agreement (taken
together, the “ELOC Agreement”) as amended May 6, 2025, the Company may elect, in our sole discretion, to issue and sell
to by White Lion Capital LLC dba White Lion GBM Innovation Fund (“White Lion”), from time to time, up to $78.9 million worth
of shares of Common Stock from after the effective date of a related registration statement until the earlier of December 31, 2026 or
the sale of all of such shares to White Lion. Any terms in initial capitals and not otherwise defined herein shall be as